1. Arinaga S, Akiyoshi T, Tsuji H (1986) Augmentation of the generation of cell-mediated cytotoxicity after a single dose of Adriamycin in cancer patients. Cancer Res 46: 4213?4216
2. Atkins M, Demchak P, Mier J, Robert N, Sznol M (1990) Phase II study of alternating interleukin-2 (IL-2) and cisplatin (CDDP) with WR-2721 (WR) in metastatic melanoma (abstract). Proc Am Soc Clin Oncol 9: 186
3. Ballas ZK (1986) Lymphokine-activated killer (LAK) cells. I. Differential recovery of LAK, natural killer cells, and cytotoxic T lymphocytes after a sublethal dose of cyclophosphamide. J Immunol 137: 2380?2384
4. Berd D, Mastrangelo MJ (1988) Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-induced T-cells. Cancer Res 48: 1671?1675
5. Blair S, Flaherty LE, Valdivieso M, Redman B (1991) Comparison of high dose interleukin-2 (HD IL-2) with combined chemotherapy/low dose IL-2 (chemo/IL-2) in metastatic malignant melanoma (MMM) (abstract). Proc Am Soc Clin Oncol 10: 294